Mostafa Ronaghi (Persian: مصطفی رونقی; born 1968) is an Iranian molecular biologist, specializing in DNA sequencing methodology. He earned his Ph.D. from the Royal Institute of Technology in Sweden in 1998.
As of 2008[update], he is the Chief Technology Officer and Senior Vice President at Illumina.[1] Prior to this position, he was a principal investigator and Senior Research Associate at the Stanford Genome Technology Center at Stanford University, focusing on developing analytical techniques for molecular diagnostics.
He is principal investigator for several grants including grants from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health[2] for the development of array-based Pyrosequencing.
In 1998, he described together with Pål Nyren and Mathias Uhlen[3] a solution-based variant of the pyrosequencing technology and co-founded Pyrosequencing AB (renamed to Biotage in 2003). He co-invented Molecular Inversion Probe assay and co-founded ParAllele BioScience to develop this multiplexed technology for genetic testing. ParAllele was acquired by Affymetrix in May 2005. In 2005, he co-founded NextBio, a search engine for life science data that was acquired by Illumina in 2013.[4] He also serves on the board of directors of IntegenX and Aurora Biofuels. In 2008, Ronaghi and Helmy Eltoukhy co-founded Avantome, a DNA sequencing company that was acquired by Illumina in July 2008.[5][6]
- ^ "Illumina | 2008 Release: Illumina Appoints Mostafa Ronaghi as Senior Vice President and Chief Technology Officer". Archived from the original on 2008-10-03. Retrieved 2008-08-04.
- ^ genome.gov | 2004 Release: NHGRI Seeks Next Generation of Sequencing Technologies
- ^ Ronaghi, M; Uhlén, M; Nyrén, P (1998). "A sequencing method based on real-time pyrophosphate". Science. 281 (5375): 363–365. doi:10.1126/science.281.5375.363. PMID 9705713. S2CID 26331871.
- ^ "Illumina | Illumina Signs Agreement to Acquire NextBio, Leader in Analyzing and Aggregating Complex Genomic Data". Archived from the original on 2014-12-26. Retrieved 2014-02-12.
- ^ tradingmarkets.com | 2008 Release: Illumina To Acquire Privately-Held Avantome For $25 Million In Cash Upfront[dead link]
- ^ Carroll, John (23 Jul 2008). "Illumina snares sequencing tech in $60M buyout". fiercebiotech.com. Questex, LLC. Retrieved 19 Oct 2019.